Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 384

1.

Structures, dipole moments and excited state lifetime of isolated 4-cyanoindole in its ground and lowest electronically excited singlet states.

Hebestreit ML, Schneider M, Lartian H, Betz V, Heinrich M, Lindic M, Choi MY, Schmitt M.

Phys Chem Chem Phys. 2019 Jun 21. doi: 10.1039/c9cp01618j. [Epub ahead of print]

PMID:
31222195
2.

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-Seropositive Recipients of Allogeneic Hematopoietic-Cell Transplantation.

Ljungman P, Schmitt M, Marty FM, Maertens J, Chemaly RF, Kartsonis NA, Butterton JR, Wan H, Teal VL, Sarratt K, Murata Y, Leavitt RY, Badshah C.

Clin Infect Dis. 2019 Jun 8. pii: ciz490. doi: 10.1093/cid/ciz490. [Epub ahead of print]

PMID:
31179485
3.

Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells.

Gong W, Hoffmann JM, Stock S, Wang L, Liu Y, Schubert ML, Neuber B, Hückelhoven-Krauss A, Gern U, Schmitt A, Müller-Tidow C, Shiku H, Schmitt M, Sellner L.

Cancer Immunol Immunother. 2019 Jul;68(7):1195-1209. doi: 10.1007/s00262-019-02354-4. Epub 2019 Jun 8.

PMID:
31177329
4.

Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.

Schubert ML, Schmitt A, Sellner L, Neuber B, Kunz J, Wuchter P, Kunz A, Gern U, Michels B, Hofmann S, Hückelhoven-Krauss A, Kulozik A, Ho AD, Müller-Tidow C, Dreger P, Schmitt M.

BMJ Open. 2019 May 19;9(5):e026644. doi: 10.1136/bmjopen-2018-026644.

5.

Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies.

Yoo HJ, Liu Y, Wang L, Schubert ML, Hoffmann JM, Wang S, Neuber B, Hückelhoven-Krauss A, Gern U, Schmitt A, Müller-Tidow C, Dreger P, Mokhir A, Schmitt M, Sellner L.

Int J Mol Sci. 2019 May 18;20(10). pii: E2469. doi: 10.3390/ijms20102469.

6.

Regulatory T cells sense effector T-cell activation through synchronized JunB expression.

Wu J, Ma S, Hotz-Wagenblatt A, Angel P, Mohr K, Schlimbach T, Schmitt M, Cui G.

FEBS Lett. 2019 May;593(10):1020-1029. doi: 10.1002/1873-3468.13393. Epub 2019 May 6.

PMID:
31017652
7.

Loss of Neurological Disease HSAN-I-Associated Gene SPTLC2 Impairs CD8+ T Cell Responses to Infection by Inhibiting T Cell Metabolic Fitness.

Wu J, Ma S, Sandhoff R, Ming Y, Hotz-Wagenblatt A, Timmerman V, Bonello-Palot N, Schlotter-Weigel B, Auer-Grumbach M, Seeman P, Löscher WN, Reindl M, Weiss F, Mah E, Weisshaar N, Madi A, Mohr K, Schlimbach T, Velasco Cárdenas RM, Koeppel J, Grünschläger F, Müller L, Baumeister M, Brügger B, Schmitt M, Wabnitz G, Samstag Y, Cui G.

Immunity. 2019 May 21;50(5):1218-1231.e5. doi: 10.1016/j.immuni.2019.03.005. Epub 2019 Apr 2.

PMID:
30952607
8.

Shaping of CD56bri Natural Killer Cells in Patients With Steroid-Refractory/Resistant Acute Graft-vs.-Host Disease via Extracorporeal Photopheresis.

Ni M, Wang L, Yang M, Neuber B, Sellner L, Hückelhoven-Krauss A, Schubert ML, Luft T, Hegenbart U, Schönland S, Wuchter P, Chen BA, Eckstein V, Krüger W, Yerushalmi R, Beider K, Nagler A, Müller-Tidow C, Dreger P, Schmitt M, Schmitt A.

Front Immunol. 2019 Mar 20;10:547. doi: 10.3389/fimmu.2019.00547. eCollection 2019.

9.

Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells.

Wang L, Gong W, Wang S, Neuber B, Sellner L, Schubert ML, Hückelhoven-Krauss A, Kunz A, Gern U, Michels B, Hinkelbein M, Mechler S, Richter P, Müller-Tidow C, Schmitt M, Schmitt A.

Cytotherapy. 2019 May;21(5):566-578. doi: 10.1016/j.jcyt.2019.02.013. Epub 2019 Mar 23.

PMID:
30910382
10.

Competition between folded and extended structures of alanylalanine (Ala-Ala) in a molecular beam.

Yatsyna V, Mallat R, Gorn T, Schmitt M, Feifel R, Rijs AM, Zhaunerchyk V.

Phys Chem Chem Phys. 2019 Mar 14. doi: 10.1039/c9cp00140a. [Epub ahead of print]

PMID:
30869702
11.

A framework for SAR-optical stereogrammetry over urban areas.

Bagheri H, Schmitt M, d'Angelo P, Zhu XX.

ISPRS J Photogramm Remote Sens. 2018 Dec;146:389-408. doi: 10.1016/j.isprsjprs.2018.10.003.

12.

Identification of Boronic Acid Derivatives as an Active Form of N-Alkylaminoferrocene-Based Anticancer Prodrugs and Their Radiolabeling with 18F.

Daum S, Toms J, Reshetnikov V, Özkan HG, Hampel F, Maschauer S, Hakimioun A, Beierlein F, Sellner L, Schmitt M, Prante O, Mokhir A.

Bioconjug Chem. 2019 Apr 17;30(4):1077-1086. doi: 10.1021/acs.bioconjchem.9b00019. Epub 2019 Mar 13.

PMID:
30768258
13.

Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients.

Stock S, Übelhart R, Schubert ML, Fan F, He B, Hoffmann JM, Wang L, Wang S, Gong W, Neuber B, Hückelhoven-Krauss A, Gern U, Christ C, Hexel M, Schmitt A, Schmidt P, Krauss J, Jäger D, Müller-Tidow C, Dreger P, Schmitt M, Sellner L.

Int J Cancer. 2019 Feb 9. doi: 10.1002/ijc.32201. [Epub ahead of print]

PMID:
30737788
14.

Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML).

Hofmann S, Schubert ML, Wang L, He B, Neuber B, Dreger P, Müller-Tidow C, Schmitt M.

J Clin Med. 2019 Feb 6;8(2). pii: E200. doi: 10.3390/jcm8020200. Review.

15.

Conformational Preferences of Isolated Glycylglycine (Gly-Gly) Investigated with IRMPD-VUV Action Spectroscopy and Advanced Computational Approaches.

Yatsyna V, Mallat R, Gorn T, Schmitt M, Feifel R, Rijs AM, Zhaunerchyk V.

J Phys Chem A. 2019 Jan 31;123(4):862-872. doi: 10.1021/acs.jpca.8b10881. Epub 2019 Jan 17.

PMID:
30608157
16.

Signatures of T and B Cell Development, Functional Responses and PD-1 Upregulation After HCMV Latent Infections and Reactivations in Nod.Rag.Gamma Mice Humanized With Cord Blood CD34+ Cells.

Theobald SJ, Khailaie S, Meyer-Hermann M, Volk V, Olbrich H, Danisch S, Gerasch L, Schneider A, Sinzger C, Schaudien D, Lienenklaus S, Riese P, Guzman CA, Figueiredo C, von Kaisenberg C, Spineli LM, Glaesener S, Meyer-Bahlburg A, Ganser A, Schmitt M, Mach M, Messerle M, Stripecke R.

Front Immunol. 2018 Nov 22;9:2734. doi: 10.3389/fimmu.2018.02734. eCollection 2018.

17.

Cell-based immunotherapy approaches for multiple myeloma.

Kriegsmann K, Kriegsmann M, Cremer M, Schmitt M, Dreger P, Goldschmidt H, Müller-Tidow C, Hundemer M.

Br J Cancer. 2019 Jan;120(1):38-44. doi: 10.1038/s41416-018-0346-9. Epub 2018 Dec 6. Review.

PMID:
30518815
18.

Reduced graphene oxide biosensor platform for the detection of NT-proBNP biomarker in its clinical range.

Munief WM, Lu X, Teucke T, Wilhelm J, Britz A, Hempel F, Lanche R, Schwartz M, Law JKY, Grandthyll S, Müller F, Neurohr JU, Jacobs K, Schmitt M, Pachauri V, Hempelmann R, Ingebrandt S.

Biosens Bioelectron. 2019 Feb 1;126:136-142. doi: 10.1016/j.bios.2018.09.102. Epub 2018 Oct 17.

PMID:
30399515
19.

Additional data for evaluation of the excited state dipole moments of anisole.

Lindic MM, Zajonz M, Hebestreit ML, Schneider M, Meerts WL, Schmitt M.

Data Brief. 2018 Oct 3;21:313-315. doi: 10.1016/j.dib.2018.09.110. eCollection 2018 Dec.

20.

Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects.

Wang L, Ni M, Hückelhoven-Krauss A, Sellner L, Hoffmann JM, Neuber B, Luft T, Hegenbart U, Schönland S, Kleist C, Sill M, Chen BA, Wuchter P, Eckstein V, Krüger W, Hilgendorf I, Yerushalmi R, Nagler A, Müller-Tidow C, Ho AD, Dreger P, Schmitt M, Schmitt A.

Front Immunol. 2018 Oct 8;9:2207. doi: 10.3389/fimmu.2018.02207. eCollection 2018.

Supplemental Content

Loading ...
Support Center